ALT-Q5 / Alteogen - LARVOL DELTA

Alteogen wins patent for antibody-drug conjugate platform for ovarian cancer (Korea Biomedical Review) - “Alteogen said Tuesday that it has registered a domestic patent for an improved antibody used in ALT-Q5, an ovarian cancer therapy, based on NexMab antibody-drug conjugate (ADC) technology used for developing ADC bio betters…The antibody inhibits the activity by binding to a protein known as folate receptor alpha (FOLR1) present on the surface of tumor cells in ovarian cancer and plays a key role in developing ADC cancer therapy. ALT-Q5 is a modified antibody that helps ADC ovarian cancer therapy target the tumor cell surface easier with enhanced antigen binding by strengthening the binding of the previously used antibody.”

Patent • Gynecologic Cancers • Oncology • Ovarian Cancer

Alteogen wins patent for antibody-drug conjugate platform for ovarian cancer (Korea Biomedical Review) - "Alteogen said Tuesday that it has registered a domestic patent for an improved antibody used in ALT-Q5, an ovarian cancer therapy, based on NexMab antibody-drug conjugate (ADC) technology used for developing ADC bio betters. The antibody inhibits the activity by binding to a protein known as folate receptor alpha (FOLR1) present on the surface of tumor cells in ovarian cancer and plays a key role in developing ADC cancer therapy. ALT-Q5 is a modified antibody that helps ADC ovarian cancer therapy target the tumor cell surface easier with enhanced antigen binding by strengthening the binding of the previously used antibody."

Patent • Genito-urinary Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer